CREDIT SUISSE AG/ - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$5,839,706
-20.7%
112,108
-3.6%
0.01%
-14.3%
Q2 2023$7,367,346
+25.1%
116,351
+7.0%
0.01%
+16.7%
Q1 2023$5,889,462
+5.8%
108,762
+3.4%
0.01%0.0%
Q4 2022$5,565,756
+54.6%
105,173
+35.9%
0.01%
+50.0%
Q3 2022$3,601,000
-14.5%
77,394
+4.9%
0.00%0.0%
Q2 2022$4,212,000
-7.2%
73,795
-0.6%
0.00%0.0%
Q1 2022$4,541,000
+53.5%
74,211
+31.3%
0.00%
+100.0%
Q4 2021$2,958,000
-73.6%
56,529
-81.2%
0.00%
-66.7%
Q3 2021$11,224,000
+476.5%
301,090
+531.1%
0.01%
+500.0%
Q2 2021$1,947,000
+10.2%
47,706
-8.4%
0.00%0.0%
Q1 2021$1,767,000
-37.7%
52,099
-41.6%
0.00%0.0%
Q4 2020$2,838,000
+102.6%
89,272
+63.5%
0.00%0.0%
Q3 2020$1,401,000
-10.9%
54,592
-10.9%
0.00%0.0%
Q2 2020$1,573,000
-30.0%
61,300
-58.1%
0.00%
-50.0%
Q1 2020$2,248,000
+164.2%
146,234
+489.7%
0.00%
+100.0%
Q4 2019$851,000
+243.1%
24,798
-25.3%
0.00%
Q3 2019$248,000
-13.6%
33,203
+49.7%
0.00%
Q2 2019$287,000
+2.5%
22,187
-3.4%
0.00%
Q1 2019$280,000
+9.4%
22,958
+2.2%
0.00%
Q4 2018$256,000
-46.0%
22,454
+2.6%
0.00%
Q3 2018$474,000
-12.5%
21,877
-28.7%
0.00%
-100.0%
Q2 2018$542,000
-29.0%
30,696
-15.4%
0.00%0.0%
Q1 2018$763,000
+32.5%
36,278
-8.7%
0.00%0.0%
Q4 2017$576,000
-5.9%
39,751
+2.5%
0.00%0.0%
Q3 2017$612,000
+175.7%
38,785
+116.9%
0.00%
Q2 2017$222,000
-34.9%
17,880
-14.7%
0.00%
Q1 2017$341,000
-38.1%
20,971
-42.7%
0.00%
-100.0%
Q4 2016$551,000
+29.3%
36,576
+30.6%
0.00%
Q3 2016$426,000
-59.3%
28,001
+3.9%
0.00%
-100.0%
Q2 2016$1,046,000
+50.1%
26,943
+7.3%
0.00%0.0%
Q1 2016$697,000
+22.5%
25,115
+137.3%
0.00%0.0%
Q4 2015$569,000
-7.0%
10,582
-30.8%
0.00%0.0%
Q3 2015$612,000
+46.1%
15,293
+16.5%
0.00%
Q2 2015$419,000
-63.3%
13,129
-72.5%
0.00%
-100.0%
Q1 2015$1,141,000
+231.7%
47,794
+134.0%
0.00%
Q2 2014$344,000
-47.9%
20,427
-43.7%
0.00%
-100.0%
Q1 2014$660,00036,3000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2022
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders